Unaudited Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ (235)	$ (24,336)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	6,047	5,122
Stock-based compensation expense	3,787	2,916
Inventory impairments and abandonments	3,181	0
Deferred and other income tax expense (benefit)	(4,266)	(763)
Gain on sale of fixed assets	(820)	0
Change in allowance for doubtful accounts	(180)	60
Equity in (income) loss of unconsolidated entities and marketable securities	(9)	1,606
Cash distributions of income from unconsolidated entities and marketable securities	33	34
Loss on extinguishment of debt	155	0
Changes in operating assets and liabilities:
Increase in accounts receivable	(3,044)	(1,511)
Decrease in income tax receivable	198	0
Increase in inventory	(44,328)	(181,765)
Decrease in other assets	3,446	2,779
Decrease in trade accounts payable	(14,983)	(5,393)
Decrease in other liabilities	(8,867)	(1,541)
Other changes	0	(124)
Net cash used in operating activities	(59,885)	(202,916)
Cash flows from investing activities:
Capital expenditures	(6,017)	(7,478)
Proceeds from sale of fixed assets	2,471	0
Investments in unconsolidated entities	(2,787)	(1,670)
Return of capital from unconsolidated entities and marketable securities	1,141	24,211
Increase in Restricted Cash	(1,770)	(2,487)
Decrease in Restricted Cash	23,392	22,259
Net cash provided by investing activities	16,430	34,835
Cash flows from financing activities:
Repayment of debt	(208,221)	(9,514)
Proceeds from issuance of new debt	137,900	0
Borrowings from credit facility	25,000	0
Repayment of borrowings from credit facility	(25,000)	0
Debt issuance costs	(2,451)	(126)
Other financing activities	(423)	(172)
Net cash used in financing activities	(73,195)	(9,812)
Decrease in cash and cash equivalents	(116,650)	(177,893)
Cash and cash equivalents at beginning of period	251,583	324,154
Cash and cash equivalents at end of period	$ 134,933	$ 146,261